Liothyronine tablets: suspected excessive and unfair pricing
- Source
- Competition and Markets Authority - Activity
- Source link
- https://www.gov.uk/cma-cases/pharmaceutical-sector-anti-competitive-conduct
- Published
- 2026-07-29 08:30:19
- Discovered by ProcIntel
- 2026-07-29 17:29:08
- Category
- M&A
- Geography
- UK
- Organisations
- —
- Significance
- Not yet scored
- Confidence
- Not yet rated
- Review status
- Pending
- Record type
- REAL
Summary
The CMA investigated alleged excessive and unfair pricing with respect to liothyronine tablets under Chapter II CA98.
Procurement Relevance Gate
FAIL
— score 7.0/100 — evaluated 2026-07-30 10:12:08
Only geographic exposure matched — no substantive content indicator, so this cannot pass alone.
- geographic_exposure (weight 8) — matched on "1 linked geography"